Hormone Refractory Prostate Cancer News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Fosun Pharma acquires exclusive rights to ReNeuron cell therapies for Chinese market
ReNeuron, a UK-based stem cell research company, announced that it has signed an exclusive license agreement with Fosun Pharma, a Chinese listed pharmaceutical company, for the development, manufacture and commercialisation of ReNeuron's CTX and hRPC cell therapy programmes in China. What ’s it about (Source: mobihealthnews)
Source: mobihealthnews - April 10, 2019 Category: Information Technology Source Type: news
Trial: Abiraterone acetate responses even after initial hormone therapy failure
(University of Colorado Anschutz Medical Campus) Results of a 40-person clinical trial published in JAMA Oncology show that 13 percent of prostate cancer patients deemed 'hormone refractory' did, in fact, have strong responses to treatment with the next-generation hormonal drug abiraterone acetate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2017 Category: Global & Universal Source Type: news
Sanofi ’s Jevtana drug receives SMC approval to treat prostate cancer
The Scottish Medicines Consortium (SMC) has accepted Sanofi Genzyme ’s Jevtana (cabazitaxel) for routine use in NHS Scotland to treat metastatic hormone-refractory prostate cancer (mHRPC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - December 14, 2016 Category: Pharmaceuticals Source Type: news
Advanced viral gene therapy eradicates prostate cancer in preclinical experiments
(Virginia Commonwealth University) Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 11, 2015 Category: Cancer & Oncology Source Type: news
Karyopharm begins Phase II trial of hormone refractory prostate cancer drug Selinexor
US-based clinical-stage pharmaceutical firm Karyopharm Therapeutics has started a Phase II trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) for treatment of patients with metastatic hormone-refractory… (Source: Drug Development Technology)
Source: Drug Development Technology - June 10, 2014 Category: Pharmaceuticals Source Type: news
ASCO: Visceral Spread Guts Prostate Ca Survival Odds
CHICAGO (MedPage Today) -- Lung, liver, and other visceral metastases are associated with the poorest survival in advanced hormone-refractory prostate cancer, according to results from a meta-analysis that sets the benchmark for prognosis. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 4, 2014 Category: Hematology Source Type: news
Hormone Refractory Breast Cancer Global Clinical Trials Review, H1,...
MarketResearch.com announces the addition of a new market research report to their product offering: Hormone Refractory Breast Cancer Global Clinical Trials Review, H1,...(PRWeb March 27, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11697174.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 27, 2014 Category: Pharmaceuticals Source Type: news
What Is Hormone Refractory Prostate Cancer?
What is hormone refractory prostate cancer? (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - June 14, 2013 Category: Cancer & Oncology Tags: health Source Type: news
Hormone therapy for endometrial cancer targets connective tissue, not tumor cells
In this study, we found that all of the progesterone anti-tumor effects are in fact mediated through the stroma, even though it makes up a minor fraction of the tumor. I believe these exciting findings are going to surprise the clinical community and change the way people look at patterns of hormone-receptor expression in endometrial tumors." The results of the three-year study, done using a specially developed laboratory model created by Memarzadeh's team that closely mimics human endometrial cancer, appear in the early online edition of Cancer Research, a peer-reviewed journal of the American Association for ...
Source: UCLA Newsroom: Health Sciences - June 13, 2013 Category: Universities & Medical Training Source Type: news
Phase III study of 2-weekly versus 3-weekly docetaxel for castration-resistant advanced prostate cancer
Source: Lancet Oncology Area: News According to the results of a Phase III study published early online in The Lancet Oncology, a 2-weekly docetaxel regimen was well tolerated and improved time to treatment failure compared with the standard 3-weekly regimen in men with hormone-refractory prostate cancer. The authors note that androgen deprivation is a standard treatment for advanced prostate cancer; it is not however curative and most patients develop castration-resistant disease within a median of 2 years. Several treatment options are available for patients with hormone-refractory prostate cancer, including ...
Source: NeLM - News - January 7, 2013 Category: Drugs & Pharmacology Source Type: news
Cleveland BioLabs to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Cleveland BioLabs, Inc. (NASDAQ: CBLI) (BOST: CBLI) today announced that the Company is scheduled to present at the Rodman & amp; Renshaw 9th Annual Global Healthcare Conference, on November 5-7, in New York City. Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer and will begin a second Phase II trial in Renal Cell Carcinoma in late 2007. Source: The...
Source: Kidney Cancer Association - October 23, 2007 Category: Urology & Nephrology Source Type: news